Hints and tips:
Related Special Reports
...Other drugmakers could still “win” the race in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly, according to the chief executive of biotech company Zealand Pharma....
...Eli Lilly and Vertex declined to comment on the talks....
...Fruergaard Jørgensen warned that new entrants faced a long road to catch up with Novo Nordisk and its US rival Eli Lilly, because of the innovation required to develop safe, effective products and the manufacturing...
...Eli Lilly chief executive David Ricks described the acquisition as “unusual” on Tuesday and called for competition authorities to look into the deal....
...The positive data will be a boon to Eli Lilly’s efforts to push for more widescale coverage of the drugs by insurers and the federal health insurance programme Medicare, which were both initially reluctant...
...Eli Lilly said that it plans to submit the results to the US Food and Drug Administration and other medicine regulators worldwide to seek approval for tirzepatide as a sleep apnoea treatment beginning this...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against US pharmacy chains such as CVS and Walgreens. Read more here...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against pharmacies such as CVS and Walgreens....
...A decision from the US Food and Drug Administration on Eli Lilly’s donanemab drug was originally due by the end of the first quarter but the breakthrough medicine will now be subject to a further review...
...Dear reader, It isn’t often that a company pays good money to criticise customers for buying its product. But that is what Eli Lilly did this week....
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
...Demand for a new class of diabetes and obesity drugs will boost US drugmaker Eli Lilly’s sales by 20 per cent in 2024, pushing its revenues above $40bn, the company said on Tuesday....
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...Amazon Pharmacy stands to generate “a lot of revenue” from drugs such as Eli Lilly’s Zepbound injection and Novo Nordisk’s Wegovy, which are both available to patients directly through the Amazon website...
...Lilly has invested billions of dollars to grow production capacity for its weight-loss treatments across sites in Germany, North Carolina and its home state of Indiana but Ricks said the company was a “long...
...Mounjaro will become available “within weeks” in Great Britain for treatment of both diabetes and obesity, after the medicines regulator authorised US pharma company Eli Lilly on Thursday to sell the weight...
...Developed respectively by Novo Nordisk and Eli Lilly, they are now being prescribed to millions of people....
...Highlighting continued caution from regulators, the agency last month delayed an approval decision on donanemab, Eli Lilly’s Alzheimer’s drug....
...US biotech Viking Therapeutics’ shares more than doubled after trial data for the company’s weight-loss drug outperformed existing treatments from drugmakers Novo Nordisk and Eli Lilly....
...The US federal drug regulator has approved Eli Lilly’s injectable diabetes medication for weight loss, as demand for the blockbuster treatments continues to surge....
...Eli Lilly lowered its expectations for full-year earnings because of accounting charges related to recent acquisitions, despite beating expectations in the third quarter driven by growth in diabetes and...
...The side effects of Eli Lilly’s and Novo Nordisk’s obesity treatments are very similar, and patients could switch from one to the other, Stanford said....
...Indianapolis-based Eli Lilly, meanwhile, has become the world’s largest pharmaceutical company on the back of sales of its drug Mounjaro for diabetes and strong trial results for its use in weight loss....
...They include the popular new diabetes and weight-loss drugs Ozempic and Wegovy, made by Novo Nordisk, and Mounjaro and Zepbound made by Eli Lilly....
...In addition, Point held about $434.8mn in cash, cash equivalents and investments at the end of June. This is a very small deal for a company as big as Eli Lilly....
International Edition